SF Prep

NPPA releases revised MRPs for 543 brands of anti-cancer medicines, effective 9 November 2026

On 28 October 2026, the National Pharmaceutical Pricing Authority released revised Maximum Retail Prices for 543 brands of anti-cancer medicines, effective from 9 November 2026.

Summary

The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, released a list of 543 brands of anti-cancer medicines with revised Maximum Retail Prices (MRPs) on 28 October 2026. The new prices take effect from 9 November 2026, and the list will be updated as manufacturers submit revised prices. The revision follows NPPA's Trade Margin Rationalisation of 137 non-scheduled anti-cancer drugs announced on 17 October 2026 to curb excessive trade margins. These drugs include immunotherapy medicines, Denosumab, Pegfilgrastim and Bevacizumab.

Key facts

Authority
National Pharmaceutical Pricing Authority (NPPA)
Under
Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers
Brands with revised MRP
543 anti-cancer brands
Effective
9 November 2026
Basis
Trade Margin Rationalisation (TMR) announced 17 October 2026
Drugs covered by TMR
137 non-scheduled anti-cancer drugs
Examples
Immunotherapy drugs, Denosumab, Pegfilgrastim, Bevacizumab

Practice MCQs 2 questions

Q1

In October 2026, NPPA released revised MRPs for how many brands of anti-cancer medicines?

Show answer

Correct answer: B — 543

NPPA released revised MRPs for 543 brands of anti-cancer medicines, effective 9 November 2026.
Q2 Advanced

The National Pharmaceutical Pricing Authority (NPPA) functions under which department?

Show answer

Correct answer: C — Department of Pharmaceuticals

NPPA functions under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.

← All current affairs